# Respiratory Syncytial Virus FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/respiratory-syncytial-virus

> No upcoming FDA catalysts in respiratory Syncytial Virus; 9 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for respiratory Syncytial Virus?

No upcoming FDA catalysts in respiratory Syncytial Virus; 9 past events are recorded. ClinicalTrials.gov: "NCT05127434 (A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-09-29." [Calendar and source filings](https://sec-api.dev/indications/respiratory-syncytial-virus)

Source: ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT05127434?tab=results (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/indications/respiratory-syncytial-virus#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 11, 2025 | [Rsvpref vaccine primary completion](https://sec-api.dev/pdufa/rsvpref-vaccine) | PFE | Respiratory Syncytial Virus | completed | "NCT06325657 (A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06325657)) |
| June 27, 2025 | [MRNA-1345 primary completion](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT06097299 (A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-08-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06097299)) |
| July 28, 2025 | [MRNA-1345 primary completion](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT05127434 (A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-09-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05127434)) |
| March 27, 2026 | [MRNA-1345 primary completion](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT07117487 (A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-27 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07117487)) |
| May 25, 2026 | [MRNA-1345 primary completion](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT06143046 (A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-25 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06143046)) |
| July 2, 2026 | [Rsvpref vaccine topline data readout](https://sec-api.dev/pdufa/rsvpref-vaccine) | PFE | Respiratory Syncytial Virus | completed | "NCT06325657 (A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06325657?tab=results)) |
| July 24, 2026 | [MRNA-1345 primary completion](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT06067230 (A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-24 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06067230)) |
| August 18, 2026 | [MRNA-1345 topline data readout](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT06097299 (A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-08-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06097299?tab=results)) |
| September 29, 2026 | [MRNA-1345 topline data readout](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT05127434 (A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-09-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05127434?tab=results)) |

## Drugs

- [Rsvpref vaccine](https://sec-api.dev/pdufa/rsvpref-vaccine) (PFE)
- [MRNA-1345](https://sec-api.dev/pdufa/mrna-1345) (MRNA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/respiratory-syncytial-virus.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Respiratory Syncytial Virus FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/respiratory-syncytial-virus

```bibtex
@misc{secapidev_indications_respiratory_syncytial_virus_20261116,
  title        = {Respiratory Syncytial Virus FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/respiratory-syncytial-virus}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_respiratory_syncytial_virus_20261116","title":"Respiratory Syncytial Virus FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/respiratory-syncytial-virus","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
